publication venue for
- Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia. 4:2962-2966. 2020
- Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism. 4:2798-2809. 2020
- Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. 4:2557-2566. 2020
- Systematic review and meta-analysis of outcomes in patients with suspected deep vein thrombosis. 4:2779-2788. 2020
- Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). 4:2460-2467. 2020
- Diagnosis of deep vein thrombosis of the upper extremity: a systematic review and meta-analysis of test accuracy. 4:2516-2522. 2020
- Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. 4:2351-2365. 2020
- A user guide to the American Society of Hematology clinical practice guidelines. 4:2095-2110. 2020
- The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. 4:2011-2017. 2020
- DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. 4:1512-1517. 2020
- Diagnosis of deep vein thrombosis of the lower extremity: a systematic review and meta-analysis of test accuracy. 4:1250-1264. 2020
- Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. 4:1539-1553. 2020
- Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines. 4:953-968. 2020
- A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. 4:728-739. 2020
- A practical approach to evaluating postoperative thrombocytopenia. 4:776-783. 2020
- Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. 4:500-513. 2020
- 2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. 3:3945-3950. 2019
- American Society of Hematology 2019 guidelines for immune thrombocytopenia. 3:3829-3866. 2019
- American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. 3:3898-3944. 2019
- American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. 3:3867-3897. 2019
- Updated international consensus report on the investigation and management of primary immune thrombocytopenia. 3:3780-3817. 2019
- Thrombus stability explains the factor V Leiden paradox: a mouse model. 3:3375-3378. 2019
- A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation. 3:1638-1646. 2019
- Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. 3:789-796. 2019
- Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis. 3:158-167. 2019
- American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. 2:3292-3316. 2018
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. 2:3226-3256. 2018
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. 2:3360-3392. 2018
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. 2:3257-3291. 2018
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. 2:3198-3225. 2018
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. 2:3317-3359. 2018
- CD19-positive antibody-secreting cells provide immune memory. 2:3163-3176. 2018
- Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. 2:3193-3195. 2018
- Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. 2:3155-3162. 2018
- A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. 2:1935-1945. 2018
- Induced pluripotent stem cell–based mapping of β-globin expression throughout human erythropoietic development. 2:1998-2011. 2018
- Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. 2:1806-1806. 2018
- Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. 2:1449-1458. 2018
- Risk of recurrent venous thromboembolism according to baseline risk factor profiles. 2:788-796. 2018
- Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. 2:529-533. 2018
- Designing a successful capacity-building program in a low-income country: the St. Joseph’s Health System–McMaster–Makerere International Outreach Program Collaboration for Uganda. 1:1-4. 2017
- Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. 1:2414-2420. 2017
- Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. 1:1827-1838. 2017
- Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. 1:1037-1046. 2017
- The direct oral anticoagulants: can we finally stop using rat poison?. 1:980-980. 2017
- Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. 1:772-778. 2017